Alzheimer's Disease

A blood test may be able to identify individuals at increased risk for developing Alzheimer’s disease symptoms, according to research presented at the Clinical Trials on Alzheimer’s Disease conference.

The American Academy of Neurology has issued ethical guidance on Aduhelm that outlines important points for neurologists to communicate to patients eligible for the treatment.

The Alzheimer's Association and collaborators announced the formation of a national database, the National Treatment and Diagnostic Alzheimer’s Registry, at the Clinical Trials on Alzheimer’s Disease conference.

Additional contingency reserves related to uncertainty surrounding the potential use of Aduhelm by individuals with Medicare contributed to projected increases in the 2022 Medicare Part B premium and deductible, according to CMS.

Patients with alopecia areata had increased risk for dementia, according to a nationwide cohort study published in Journal of Clinical Psychiatry.

Reproductive history events indicating more estrogen exposure correlated with larger gray matter volume in midlife women, according to a study published in Neurology.

Estimating treatment effects on caregivers can help determine the cost-effectiveness of treatments for Alzheimer’s disease, according to results of an economic evaluation published in JAMA Network Open.

Healio’s most-viewed neurology stories in October highlight cognitive impairment after COVID-19 infection, vaccine risks and advances in Alzheimer’s therapies, including the FDA granting breakthrough therapy designation for gantenerumab.

The FDA has granted breakthrough therapy designation to gantenerumab, an anti-amyloid beta antibody developed for subcutaneous administration, as an Alzheimer’s disease treatment.

NIH Director Francis S. Collins, MD, PhD, who has served under three U.S. presidents, will step down from the position by the end of the year, according to an agency press release.